India and several other WTO-member countries are now compliant with international patent rights. Paroma Basu investigates the potential impact on biotech.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pharmacogenomic technologies: a necessary "luxury" for better global public health?
Globalization and Health Open Access 24 August 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Indian biogenerics industry emerges
Related external links
The Swiss Embassy’s Report on Biotechnology Industry in India (2004)
Rights and permissions
About this article
Cite this article
Basu, P. International patent law—boon or bane of biotech?. Nat Biotechnol 23, 13–15 (2005). https://doi.org/10.1038/nbt0105-13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0105-13
This article is cited by
-
Pharmacogenomic technologies: a necessary "luxury" for better global public health?
Globalization and Health (2011)
-
The road to recovery
Nature (2007)
-
Erratum: International patent law—boon or bane of biotech?
Nature Biotechnology (2005)